Greenhouse Funds LLLP Has $77.49 Million Position in NeoGenomics, Inc. (NASDAQ:NEO)

Greenhouse Funds LLLP boosted its stake in NeoGenomics, Inc. (NASDAQ:NEO - Free Report) by 5.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,701,897 shares of the medical research company's stock after buying an additional 237,491 shares during the quarter. NeoGenomics makes up about 3.2% of Greenhouse Funds LLLP's holdings, making the stock its 17th biggest position. Greenhouse Funds LLLP owned about 3.66% of NeoGenomics worth $77,487,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of NEO. PNC Financial Services Group Inc. grew its holdings in NeoGenomics by 5.2% in the 4th quarter. PNC Financial Services Group Inc. now owns 15,610 shares of the medical research company's stock valued at $257,000 after buying an additional 770 shares in the last quarter. Summit Investment Advisors Inc. raised its stake in NeoGenomics by 6.9% in the 4th quarter. Summit Investment Advisors Inc. now owns 13,339 shares of the medical research company's stock worth $220,000 after purchasing an additional 863 shares in the last quarter. Blue Trust Inc. grew its position in shares of NeoGenomics by 33.2% during the 4th quarter. Blue Trust Inc. now owns 4,421 shares of the medical research company's stock worth $73,000 after purchasing an additional 1,103 shares in the last quarter. Versant Capital Management Inc increased its holdings in shares of NeoGenomics by 174.9% during the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company's stock worth $30,000 after purchasing an additional 1,142 shares during the period. Finally, SBI Securities Co. Ltd. bought a new position in shares of NeoGenomics during the fourth quarter worth approximately $26,000. Institutional investors and hedge funds own 98.50% of the company's stock.

NeoGenomics Price Performance

Shares of NASDAQ NEO traded up $0.18 during midday trading on Friday, reaching $10.27. 1,432,237 shares of the company were exchanged, compared to its average volume of 966,356. The stock's 50-day moving average price is $9.84 and its 200-day moving average price is $13.50. The stock has a market cap of $1.32 billion, a P/E ratio of -16.56 and a beta of 1.41. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. NeoGenomics, Inc. has a one year low of $8.05 and a one year high of $19.12.

NeoGenomics (NASDAQ:NEO - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share for the quarter, missing analysts' consensus estimates of $0.03 by ($0.05). The firm had revenue of $172.00 million for the quarter, compared to the consensus estimate of $173.40 million. NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. On average, sell-side analysts anticipate that NeoGenomics, Inc. will post -0.2 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on NEO shares. Needham & Company LLC lowered their price objective on NeoGenomics from $19.00 to $18.00 and set a "buy" rating on the stock in a research note on Wednesday, February 19th. Bank of America dropped their price target on NeoGenomics from $19.00 to $16.00 and set a "neutral" rating for the company in a research note on Wednesday, February 19th. The Goldman Sachs Group reduced their price objective on shares of NeoGenomics from $17.00 to $15.00 and set a "buy" rating on the stock in a research note on Thursday, April 17th. Piper Sandler dropped their target price on shares of NeoGenomics from $21.00 to $18.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Finally, Benchmark lowered shares of NeoGenomics from a "buy" rating to a "hold" rating in a research report on Monday, January 13th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat, NeoGenomics has an average rating of "Moderate Buy" and an average price target of $19.30.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.